{
  "patient_id": "MBC_003",
  "subtype": "HER2+",
  "biomarker_summary": {
    "ER": "negative",
    "PgR": "negative",
    "HER2": "positive",
    "PIK3CA": "wild_type",
    "BRCA1": "wild_type",
    "BRCA2": "wild_type",
    "PALB2": "wild_type",
    "MSI": "stable",
    "TMB": 4.1
  },
  "treatment_history_summary": "Treatment-naive",
  "recommendations": [
    {
      "treatment": "Trastuzumab \u00b1 Pertuzumab without chemo",
      "evidence_level": "III",
      "recommendation_strength": "Weak",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Breast Cancer Subtype Classification -> HER2\u2011Positive Breast Cancer -> Chemotherapy Contraindicated & HR\u2011Negative",
      "rationale": "Patient has HER2+ metastatic breast cancer. HER2-positive status supports anti-HER2 therapy.",
      "keywords": [
        "systemic therapy",
        "HER2 targeting",
        "anti-HER2",
        "metastatic breast cancer",
        "pertuzumab",
        "trastuzumab"
      ]
    }
  ],
  "total_recommendations": 1
}